139 related articles for article (PubMed ID: 21350317)
1. Calcitriol treatment attenuates inflammation and oxidative stress in hemodialysis patients with secondary hyperparathyroidism.
Wu CC; Chang JH; Chen CC; Su SB; Yang LK; Ma WY; Zheng CM; Diang LK; Lu KC
Tohoku J Exp Med; 2011 Mar; 223(3):153-9. PubMed ID: 21350317
[TBL] [Abstract][Full Text] [Related]
2. Effects of calcitriol on type 5b tartrate-resistant acid phosphatase and interleukin-6 in secondary hyperparathyroidism.
Lu KC; Tseng CF; Wu CC; Yeung LK; Chen JS; Chao TY; Janckila AJ; Yam LT; Chu P
Blood Purif; 2006; 24(5-6):423-30. PubMed ID: 16888370
[TBL] [Abstract][Full Text] [Related]
3. Calcitriol treatment increases serum levels of the soluble receptor of advanced glycation end products in hemodialysis patients with secondary hyperparathyroidism.
Sung JY; Chung W; Kim AJ; Kim HS; Ro H; Chang JH; Lee HH; Jung JY
Tohoku J Exp Med; 2013 May; 230(1):59-66. PubMed ID: 23748365
[TBL] [Abstract][Full Text] [Related]
4. Decreased blood lead levels after calcitriol treatment in hemodialysis patients with secondary hyperparathyroidism.
Lu KC; Wu CC; Ma WY; Chen CC; Wu HC; Chu P
Bone; 2011 Dec; 49(6):1306-10. PubMed ID: 21985997
[TBL] [Abstract][Full Text] [Related]
5. Cholecalciferol Additively Reduces Serum Parathyroid Hormone Levels in Severe Secondary Hyperparathyroidism Treated with Calcitriol and Cinacalcet among Hemodialysis Patients.
Zheng CM; Wu CC; Hung CF; Liao MT; Shyu JF; Hsu YH; Lu CL; Wang YH; Zheng JQ; Chang TJ; Lin YF; Lu KC
Nutrients; 2018 Feb; 10(2):. PubMed ID: 29439405
[TBL] [Abstract][Full Text] [Related]
6. Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial.
Moe S; Wazny LD; Martin JE
Can J Clin Pharmacol; 2008; 15(1):e36-43. PubMed ID: 18192704
[TBL] [Abstract][Full Text] [Related]
7. Bio-intact parathyroid hormone and intact parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism receiving intravenous calcitriol therapy.
Fujimori A; Sakai M; Yoshiya K; Shin J; Kim JI; Inaba Y; Miyamoto T; Inoue S; Fukagawa M
Ther Apher Dial; 2004 Dec; 8(6):474-9. PubMed ID: 15663547
[TBL] [Abstract][Full Text] [Related]
8. Predicting the effect of intravenous calcitriol on parathyroid gland activity using double-phase technetium Tc 99m-sestamibi scintigraphy.
Torregrosa JV; Fuster D; Ybarra J; Ortín J; Moreno A; Valveny N
Am J Kidney Dis; 2004 Sep; 44(3):476-80. PubMed ID: 15332220
[TBL] [Abstract][Full Text] [Related]
9. Redox State of Human Serum Albumin and Inflammatory Biomarkers in Hemodialysis Patients with Secondary Hyperparathyroidism During Oral Calcitriol Supplementation for Vitamin D.
Nasif WA; Mukhtar MH; El-Emshaty HM; Alwazna AH
Open Med Chem J; 2018; 12():98-110. PubMed ID: 30450134
[TBL] [Abstract][Full Text] [Related]
10. Vitamin D receptor activator reduces oxidative stress in hemodialysis patients with secondary hyperparathyroidism.
Tanaka M; Tokunaga K; Komaba H; Itoh K; Matsushita K; Watanabe H; Kadowaki D; Maruyama T; Otagiri M; Fukagawa M
Ther Apher Dial; 2011 Apr; 15(2):161-8. PubMed ID: 21426509
[TBL] [Abstract][Full Text] [Related]
11. Effects of Denosumab and Calcitriol on Severe Secondary Hyperparathyroidism in Dialysis Patients With Low Bone Mass.
Chen CL; Chen NC; Liang HL; Hsu CY; Chou KJ; Fang HC; Lee PT
J Clin Endocrinol Metab; 2015 Jul; 100(7):2784-92. PubMed ID: 25955225
[TBL] [Abstract][Full Text] [Related]
12. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
Ogata H; Koiwa F; Shishido K; Takahashi K; Ito H; Kinugasa E; Taguchi S
Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
[TBL] [Abstract][Full Text] [Related]
13. Effect of intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients.
Liou HH; Chiang SS; Tsai SC; Chang CC; Wu SC; Shieh SD; Huang TP
Zhonghua Yi Xue Za Zhi (Taipei); 1994 Jun; 53(6):319-24. PubMed ID: 8087705
[TBL] [Abstract][Full Text] [Related]
14. Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidism.
Akizawa T; Akiba T; Hirakata H; Kinugasa E; Tominaga Y; Fukagawa M; Yokoyama K; Zhang W; Linde PG; Suzuki M
Ther Apher Dial; 2015 Jun; 19(3):225-34. PubMed ID: 25363733
[TBL] [Abstract][Full Text] [Related]
15. Alterations in serum phosphate levels predict the long-term response to intravenous calcitriol therapy in dialysis patients with secondary hyperparathyroidism.
Hosaka K; Kazama JJ; Yamamoto S; Ito Y; Iino N; Maruyama H; Saito A; Narita I; Gejyo F
J Bone Miner Metab; 2008; 26(2):185-90. PubMed ID: 18301976
[TBL] [Abstract][Full Text] [Related]
16. Long-term effects of small doses of calcitriol in hemodialysis patients with moderate secondary hyperparathyroidism.
Vlassopoulos D; Noussias C; Revenas K; Hadjilouka-Mantaka A; Arvanitis D; Tzortzis G; Hadjiconstantinou V
Ren Fail; 1999 Mar; 21(2):199-207. PubMed ID: 10088180
[TBL] [Abstract][Full Text] [Related]
17. Comparison of oral falecalcitriol and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism: a randomized, crossover trial.
Ito H; Ogata H; Yamamoto M; Takahashi K; Shishido K; Takahashi J; Taguchi S; Kinugasa E
Clin Nephrol; 2009 Jun; 71(6):660-8. PubMed ID: 19473635
[TBL] [Abstract][Full Text] [Related]
18. Acute effects of repetitive hemodialysis on circulating immunoreactive parathyroid hormone levels in uremic patients undergoing vitamin D (calcitriol) therapy.
Bellazzi R; Romanini D; Bacchella L; Nai M; Aprile C; Santagostino M; De Vincenzi A
Nephron; 1991; 57(3):273-82. PubMed ID: 2017266
[TBL] [Abstract][Full Text] [Related]
19. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
20. Serum parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D3 in patients on maintenance haemodialysis.
Rassoul Z; Mousa D; Rehman MA; Abdalla AH; Hawas F; Popovich W; Gaisoum M; al-Sulaiman M; Al-Khader A
Am J Nephrol; 1995; 15(6):507-11. PubMed ID: 8546173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
